Total Funding
$762.5M
Employee Range
11-50
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.
Amolyt Pharma data powered by:
Share
Amolyt Pharma data powered by:
Amolyt PharmaOverall Ranking
Regional Rank
Share
Loading...
In Western Europe
Top null%out of startups
Amolyt PharmaIndustry Rankings in
Healthtech
City Rank
Share
1st
In Écully
Top 50%out of 2 startups
National Rank
Share
75th
In France
Top 16%out of 473 startups
Regional Rank
Share
497th
In Western Europe
Top 11%out of 4551 startups
Amolyt PharmaSubindustry Rankings in
BiotechnologyCity Rank
Share
1st
In Écully
Top 100%out of 1 startups
National Rank
Share
19th
In France
Top 9%out of 214 startups
Regional Rank
Share
170th
In Western Europe
Top 10%out of 1726 startups
rankings by:
Amolyt PharmaSB Rank Evolution
Not enough data points to display the chart.
Amolyt PharmastartupComparison
National Ranking (undefined)
Loading...
...
Regional Ranking (undefined)
Loading...
...
Global Ranking (WorldWide)
Loading...
...
Industry Ranking (undefined)
Loading...
...
SubIndustry Ranking (undefined)
Loading...
...
See all ranked entities with a premium subscription
Get Pro